Human Evidence and Safety of Incretin Medicines and Growth-Hormone Peptides

Welcome to the final lesson of this introductory module. Previously, we separated mechanisms from outcomes: incretin medicines mainly make an energy deficit easier through appetite and intake effects, while GH-axis agents can alter lipolysis, growth signalling, fluid balance, and glucose metabolism without automatically producing net fat loss or meaningful new muscle.

Now we ask the decision-relevant question: what have human studies actually shown? We will assess weight loss, fat loss, and lean-tissue changes; distinguish regulated medicines from poorly evidenced “research peptide” use; and put common side effects, serious risks, and evidence gaps into a proportionate risk–benefit framework.

For someone focused on getting lean while retaining performance and muscle, the key conclusion will be nuanced: large fat-dominant weight loss is well demonstrated for approved incretin medicines in their studied populations, but measured “lean mass” does fall and is not equivalent to skeletal-muscle loss. GH-axis agents have a much narrower evidence base for this purpose, with more substantial metabolic and safety trade-offs than online discussion often suggests.

---

Start with the endpoint: what exactly was lost?

“Lost 20% body weight” is an impressive result, but it is not a body-composition result. For that, we need to separate:

$$\Delta W=\Delta FM+\Delta LST+\Delta BMC$$

where:

• $W$ is body weight;
• $FM$ is fat mass;
• $LST$ is lean soft tissue;
• $BMC$ is bone mineral content.

The usual shorthand is even rougher: “fat mass” versus “lean mass” or “fat-free mass.” This becomes important because lean mass is not synonymous with contractile skeletal muscle. Depending on the measurement method, it includes water, glycogen, organs, connective tissue, and sometimes changes associated with intramuscular fat.

A DXA scan is useful, reproducible, and widely used in large trials, but it cannot tell us precisely how much change occurred in muscle fibres themselves. In a rapid deficit, reduced glycogen and associated water alone can make measured lean tissue decline. Conversely, a small increase in “lean mass” is not proof of hypertrophy: it may reflect water retention, which is especially relevant for GH.

Therefore, evaluate a body-composition claim using four questions:

1. How much total weight was lost, relative to placebo or a comparator?
2. Was the loss predominantly fat? Look at absolute fat mass and visceral fat, not only the percentage of lost weight labelled “lean.”
3. What did the instrument measure? DXA-derived lean tissue, BIA-derived fat-free mass, MRI muscle volume, and strength are different outcomes.
4. What happened to function? Strength, mobility, training performance, and bone health matter more than a single compartment number.

This is analogous to evaluating an investment strategy from accounting statements: a headline return is insufficient unless you know its composition, measurement convention, comparator, and risk taken to achieve it.

The video is directionally useful, but retain one methodological caution: it is fair to say that DXA lean mass is an imperfect proxy for muscle; it is too strong to claim that every observed lean-mass reduction is merely water or glycogen. Some loss of muscle tissue is expected during substantial weight loss. The empirical question is whether it is disproportionate, functionally harmful, or avoidable.

---

Incretin medicines: strong evidence for weight loss, fat-dominant rather than muscle-selective loss

The highest-quality evidence in this lesson is for approved incretin-based medicines—especially semaglutide and tirzepatide—in adults with obesity or overweight, often with weight-related comorbidities. These are large randomized, double-blind, placebo-controlled trials conducted alongside dietary and activity advice.

Semaglutide

In the pivotal 68-week semaglutide obesity trial reported in the Wegovy prescribing information, mean body-weight change was:

• Semaglutide: $-14.9\%$
• Placebo: $-2.4\%$

So the placebo-adjusted difference was approximately 12.4 percentage points. In the semaglutide group, 66.1% reached at least 10% weight loss and 47.9% reached at least 15%; corresponding placebo figures were 12.0% and 4.8%.

Those are mean and categorical trial results, not promises to an individual. Participants received structured lifestyle advice, and trial populations were generally much heavier than a trained person attempting to go from moderately lean to very lean. Extrapolating either efficacy or tolerability to a bodybuilding cut is therefore uncertain.

The STEP 1 DXA substudy gives the relevant composition result: semaglutide lowered total fat mass by 19.3%, visceral fat by 27.4%, and lean body mass by 9.7%. Thus, fat and central fat fell more than lean mass in proportional terms, and the proportion of body weight that was lean increased despite an absolute reduction in lean mass.

Tirzepatide

Tirzepatide, the dual GIP/GLP-1 agonist, produced still larger average losses in SURMOUNT-1: roughly 15–21% body weight over 72 weeks depending on dose.

Its DXA substudy is particularly useful because it reports absolute compartments. Average loss was approximately:

Outcome over 72 weeks	Tirzepatide result
Total weight	about 21.5 kg
Fat mass	about 15.9 kg
Lean soft tissue	about 5.6 kg
Partition of weight lost	about 74% fat, 26% lean soft tissue

The clean inference is fat-dominant weight loss, not “no lean-tissue loss.” A 5.6 kg average reduction in lean soft tissue is substantial in absolute terms, particularly for older adults, people with low muscle reserve, or anyone unable to train adequately during treatment.

It is also not evidence that tirzepatide removes 5.6 kg of muscle protein. Lean soft tissue includes water and non-muscle tissue, and MRI work has found reductions in muscle fat infiltration alongside lower muscle volume. A smaller muscle cross-sectional area with less intramuscular fat is not automatically a deterioration in muscle quality.

Is incretin-related lean loss unusually bad?

Current evidence does not demonstrate that approved GLP-1-based treatment causes uniquely unfavourable tissue partitioning compared with other ways of losing a large amount of weight. Across trial and meta-analytic evidence, fat accounts for the majority of weight lost; lean tissue commonly accounts for roughly one-quarter to one-third, although the exact estimate depends on the drug, the degree and rate of loss, and the measurement method.

That comparison is the right one. It is not useful to compare pharmacological weight loss against an imaginary scenario in which someone loses a large amount of fat while retaining every gram of non-fat tissue. The realistic alternatives are:

• continued high body weight;
• lifestyle-only weight loss, which is often smaller and difficult to sustain;
• intentional calorie restriction, which also lowers fat-free mass;
• bariatric surgery, which can produce large fat loss but also meaningful fat-free-mass loss.

Still, “not uniquely bad” does not mean “irrelevant.” If the objective is both improved health and physique retention, the modifiable variables remain familiar:

• an appropriately paced deficit;
• adequate protein and diet quality;
• resistance training with progressive loading;
• maintaining daily movement;
• monitoring strength, performance, symptoms, and nutritional adequacy.

The evidence for resistance training and adequate protein is stronger than evidence for expensive “muscle-preserving” supplement stacks. Direct trials of optimised training and protein strategies specifically during semaglutide or tirzepatide treatment remain limited, so this is a sensible extrapolation from broader weight-loss and resistance-training evidence—not a settled GLP-1-specific protocol.

The maintenance finding: the drug effect is usually ongoing, not permanent

In a semaglutide withdrawal design, people who had already completed a run-in period and then switched to placebo regained weight, whereas those continuing treatment lost further weight. That is consistent with the mechanism from the previous lesson: stopping the medicine removes its continuing effect on appetite, food reward, and intake.

It does not mean the medicine “failed,” nor does it prove that everyone must take it indefinitely. It does mean that claims of a permanent metabolic reset should be treated skeptically. Long-term maintenance, discontinuation strategy, cost, tolerability, and behavioural support are practical uncertainties rather than side issues.

---

Incretin adverse effects: distinguish frequent discomfort from rare but important risk

The most common downside of GLP-1-based treatment is gastrointestinal. That is not a trivial footnote: it affects adherence, hydration, food quality, protein intake, training quality, and ultimately whether treatment is appropriate for a particular person.

For semaglutide 2.4 mg in obesity trials, the Wegovy label reports the following common adverse reactions:

Adverse reaction	Wegovy	Placebo
Nausea	44%	16%
Diarrhoea	30%	16%
Vomiting	24%	6%
Constipation	24%	11%
Abdominal pain	20%	10%
Fatigue	11%	5%

These figures are specific to this semaglutide dose and trial context; they should not be treated as universal rates for every incretin medicine. Symptoms often cluster during dose escalation, and severity varies considerably. In the same program, 6.8% of semaglutide-treated participants permanently discontinued because of adverse effects, versus 3.2% on placebo.

The key physique-relevant point is that nausea, early satiety, food aversion, vomiting, and constipation can make a high-protein, nutrient-dense diet harder to execute. Appetite suppression is the intended mechanism for energy intake; it cannot be assumed to select for adequate protein, fibre, minerals, or hydration.

Serious or clinically important risks

A disciplined risk discussion should not claim either that these agents are harmless or that every labelled event is common and proven to be directly caused by the drug.

Issue	What the evidence supports	Practical interpretation
Gallstones and gallbladder inflammation	Higher incidence than placebo is observed. In adult Wegovy trials, cholelithiasis was 1.6% versus 0.7%; cholecystitis 0.6% versus 0.2%.	Rapid weight loss itself raises gallstone risk, but the drug group showed a higher rate even after considering weight loss. This is a genuine safety consideration.
Pancreatitis	Acute pancreatitis has been observed and is a labelled warning; it was rare in the trials.	A rare-event trial signal cannot settle causality or precisely estimate risk in every subgroup. Persistent severe abdominal pain requires prompt medical assessment, not online diagnosis.
Dehydration and kidney injury	Vomiting and diarrhoea can cause volume depletion; post-marketing acute kidney injury reports exist.	Risk is especially relevant with severe gastrointestinal symptoms or pre-existing renal impairment.
Hypoglycaemia	The risk is higher for people with diabetes using insulin or insulin secretagogues.	GLP-1 therapy by itself is not typically discussed like insulin misuse, but drug combinations matter.
Diabetic retinopathy complications	More events were seen in a relevant diabetes trial, especially among people with pre-existing retinopathy; rapid glucose improvement is a plausible contributor.	This is primarily a diabetes-management issue requiring clinical monitoring, not a general claim that these medicines cause blindness.
Thyroid C-cell tumours	Semaglutide caused C-cell tumours in rodents. Human relevance remains unknown.	Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. This is not evidence that it causes thyroid cancer in humans, but it is not something to dismiss.
Heart-rate rise and hypersensitivity	Small average resting-heart-rate increases occur; serious allergic reactions have been reported.	Usually not the main limiting issue, but relevant in individual risk assessment.

Two evidence principles matter here:

1. Absence of a clear large signal is not proof of zero risk. Rare events can be difficult to identify even in large trials.
2. A post-marketing report establishes a signal to investigate, not a frequency or a causal estimate. People taking a common drug will experience illnesses that also occur in the general population.

The appropriate response to uncertainty is neither casual self-experimentation nor blanket alarmism. It is regulated prescribing, appropriate screening, gradual titration when indicated, and monitoring tailored to the person’s medical context.

---

GH-axis agents: a far less persuasive fat-loss or muscle-building evidence base

The GH axis is frequently bundled with incretins in peptide discussions, yet the quality and relevance of evidence are very different.

Recombinant GH: replacement medicine is not physique enhancement evidence

In adults with confirmed GH deficiency, clinically supervised GH replacement can improve body composition and some health measures. That is treatment of a defined endocrine disorder. It does not establish that giving supraphysiological GH to a healthy, resistance-trained adult is a safe or effective way to get leaner or build functional muscle.

In healthy adults, exogenous GH can reduce fat mass and increase measured fat-free or lean mass. But several cautions are central:

• increases in fat-free mass can partly reflect extracellular fluid retention, not muscle hypertrophy;
• evidence for improved strength, sprint performance, or sport-relevant performance is much less convincing than the change in body-composition compartments;
• GH can worsen insulin sensitivity and raise blood glucose;
• adverse effects are dose-related and can include oedema, joint pain, carpal-tunnel symptoms, paraesthesia, and insulin resistance.

With chronic excessive GH exposure, the biological direction is acromegaly-like: enlargement of soft tissues and organs, sleep-apnoea risk, hypertension and cardiac changes, glucose intolerance, and potentially serious long-term morbidity. That is a poor trade for a speculative improvement in a trained person’s body composition.

Tesamorelin: a legitimate but narrow case

Tesamorelin is a GHRH analogue, not GH itself. In the United States, it is approved to reduce excess abdominal fat in people with HIV-associated lipodystrophy. This is a highly specific indication and population; it should not be represented as general evidence for healthy bodybuilding use.

The figure below illustrates an important type of outcome: regional tissue measurements rather than only scale weight.

The figure supports a restrained conclusion: in the studied clinical population, tesamorelin was associated with improved visceral and hepatic fat-related measures. It does not establish a general “fat-loss peptide” effect, a bodybuilding benefit, or an increase in skeletal muscle.

Tesamorelin also raises IGF-1 and can cause adverse effects including fluid retention, joint symptoms, injection-site reactions, and glucose intolerance. Its biological route—raising GH-axis activity—does not eliminate the risks inherent in that route. Furthermore, changes in visceral fat may reverse after discontinuation.

“Research peptides” and GH secretagogues

GHRH analogues and ghrelin-pathway secretagogues are often marketed or discussed as if their effects can be inferred from a GH or IGF-1 blood result. That is a category error.

A rise in GH or IGF-1 is a biomarker response. It does not prove:

• sustained fat loss;
• preferential loss of visceral over subcutaneous fat in healthy people;
• new contractile muscle;
• improved lifting performance;
• safety over months or years.

Ghrelin-receptor agonists deserve particular skepticism in the context of cutting because they can increase hunger. A substance may increase GH secretion and still work against the principal behavioural requirement for fat loss: maintaining a manageable energy deficit.

The main safety uncertainty is often not merely pharmacology. With unapproved “research peptide” products, there may be no validated product identity, dose accuracy, sterility, cold-chain integrity, or adverse-event surveillance. Even a plausible molecule studied under medical supervision is not equivalent to a vial sold through an unregulated market.

---

A practical evidence hierarchy for body-composition claims

When you hear that a peptide “burns fat,” “protects muscle,” or “recomps,” place the claim in this hierarchy:

Level of claim	Example	Evidential status
Receptor or biomarker effect	“It raises GH/IGF-1”	May be true, but does not answer the body-composition question
Acute physiological effect	“It increases lipolysis”	Plausible, but does not prove net fat loss
Short-term compartment change	“DXA lean mass rose”	Requires scrutiny of water, glycogen, and measurement method
Clinical body-composition outcome	“Fat mass fell more than lean soft tissue in a randomized trial”	Stronger, especially with a comparator
Functional and long-term outcome	“Strength, physical function, bone health, safety, and maintenance remained favourable”	Most decision-relevant, and often least available for research peptides

For approved incretin medicines, we have meaningful evidence through the fourth level and growing evidence on longer-term outcomes. For GH-axis agents in specific medical indications, we have targeted evidence for particular outcomes. For most physique-oriented research-peptide claims, evidence often stops at the first or second level.

---

Key takeaways

• Semaglutide and tirzepatide have strong randomized-trial evidence for large weight loss in adults with obesity or overweight, typically around 15% and up to roughly 20% or more, respectively, in their pivotal trial settings.
• Their weight loss is generally fat-dominant, with meaningful reductions in visceral and ectopic fat. Absolute lean tissue also declines.
• Lean mass, fat-free mass, and skeletal muscle are not interchangeable. DXA results should not be converted directly into claims that a person has lost the same amount of muscle tissue.
• There is no convincing evidence that approved incretin medicines are uniquely muscle-wasting relative to substantial weight loss by other means. But muscle retention remains an active practical concern, especially during rapid loss or in people with low reserve.
• For preserving physique and function, resistance training, sufficient protein, nutritional adequacy, and monitoring performance are higher-confidence levers than peptide “muscle protection” claims.
• GI adverse effects are common with GLP-1 medicines and can materially affect adherence, hydration, diet quality, and training. Gallbladder disease, pancreatitis warnings, dehydration-related kidney injury, and subgroup-specific risks require appropriate medical oversight.
• GH and GH-axis manipulation are not evidence-based shortcuts to lean mass or fat loss in healthy lifters. Measured lean-mass gains may partly be fluid; glucose intolerance and acromegaly-like adverse effects are important trade-offs.
• Tesamorelin has a specific clinical evidence base for HIV-associated abdominal lipodystrophy, not for general cutting or bodybuilding.
• For an unapproved peptide, uncertainty includes not only outcome evidence and adverse effects, but also product quality and the lack of systematic safety surveillance.

This completes the primer. The durable habit to retain is simple: when encountering a peptide claim, identify the population studied, comparator, endpoint, measurement method, absolute effect, and safety follow-up before treating a mechanistic story as a useful body-composition intervention.